The Xen45 gel stent can provide long-term IOP reduction in patients with refractory glaucoma while offering a more favorable safety profile as well as relief from multiple ocular symptoms, according to a poster presented at the American Academy of Ophthalmology meeting in New Orleans.
“The improvement in symptoms is likely related to reduced medication use,” Joseph F. Panarelli, MD, lead author of the poster, said in a follow-up interview with Ocular Surgery News.
The Xen45 gel stent (Allergan) is a MIGS device that is implanted ab interno to create a (Read more...)
Uncategorized